{"id":495270,"date":"2020-07-10T16:18:01","date_gmt":"2020-07-10T16:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=495270"},"modified":"2020-07-10T16:18:01","modified_gmt":"2020-07-10T16:18:01","slug":"psoriasis-treatment-market-size-value-growth-estimation-future-trends-sales-projection-covid19-impact-analysis-and-leading-players-by-2025","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-treatment-market-size-value-growth-estimation-future-trends-sales-projection-covid19-impact-analysis-and-leading-players-by-2025_495270.html","title":{"rendered":"Psoriasis Treatment Market Size Value, Growth Estimation, Future Trends, Sales Projection, COVID-19 Impact Analysis and Leading Players By 2025"},"content":{"rendered":"
\"Psoriasis<\/a><\/p>\n
\n
Psoriasis Treatment Market<\/div>\n<\/div>\n<\/div>\n
Psoriasis Treatment Market Size, Growth and Share Analysis by Drug Class [Tumour Necrosis Factor Inhibitors, Interleukin-Inhibitors, Vitamin D Analogues, Treatment Type, Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics and Regional Insights (Americas, Europe, Asia-Pacific and Middle East & Africa), Forecast to 2025<\/div>\n

Psoriasis Treatment Market Size, Growth and Share Analysis by Drug Class [Tumour Necrosis Factor Inhibitors, Interleukin-Inhibitors, Vitamin D Analogues, Treatment Type, Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics and Regional Insights (Americas, Europe, Asia-Pacific and Middle East & Africa), Forecast to 2025<\/strong><\/p>\n

Psoriasis Treatment Market Analysis<\/p>\n

The Global Psoriasis Treatment Market<\/a> size is expected to reach USD 13.1 billion at a CAGR of 7.3% over the forecast period. Psoriasis is a skin disorder characterized by scales, rashes, and dry patches. Research on psoriasis and its effective treatments have been linked to genetics and lapses in the immunity system. The global psoriasis treatment market report by Market Research Future (MRFR) contains drivers, challenges, trends, and opportunities for the period of 2019 to 2025 (forecast period). Conduction of clinical trials and therapies for this skin disorder due to its prevalence in developed and developing countries will drive the need for antibodies and antagonists.<\/p>\n

Major drivers of the market include investments in research and development into novel personalized therapies, awareness of the treatment, and encouragement for the growth of new technologies. High prevalence of psoriasis is the primary driver of the market. According to the National Psoriasis Foundation, more than 8 million Americans have psoriasis. It is prevalent in all races and affects patients commonly in the range of 50 to 69.<\/p>\n

Request Free Sample Copy at:<\/strong> https:\/\/www.marketresearchfuture.com\/sample_request\/2769<\/strong><\/a><\/p>\n

The use of novel biomarkers for investigating the pathogenesis of psoriasis will bolster the market demand owing to its role in its early diagnosis. Results of these biomarkers are validated via techniques such as Western blot, ELISA, IHC, and qRT-PCR. Recently, etanercept, adalimumab, and infliximab have successful targeted tumour necrosis factor alpha (TNF-α) successfully and prevented its adhesion to its receptor in cells.<\/p>\n

Psoriasis treatment market Competitive Landscape<\/p>\n

major players in the global psoriasis treatment market are<\/p>\n

• Eli Lilly and Company
• Amgen 
• AstraZeneca 
• Merck and Co. Inc 
• Novartis International AG 
• Celgene Corporation 
• Pfizer Inc 
• AbbVie 
• Johnson & Johnson <\/p>\n

The industry is complex with medications as a first line of treatment for cases of psoriasis based on the severity of their indication.<\/p>\n

Psoriasis Treatment Market Segmentation<\/p>\n

The global psoriasis treatment market is segmented by drug class and treatment type.<\/p>\n

Based on treatment, the global psoriasis treatment market is segmented into biologics, topicals, and systemic. Biologics is sub-segmented into tumour necrosis factor-alpha (TNF-a) inhibitors, InterleU.K.in 12 and 23 (IL-12\/23) inhibitors, InterleU.K.in 17 (IL-17) inhibitor, and T cell inhibitor. Similarly, topicals are further sub-segmented into topical steroids, over the counter (OTC) topicals, and topical non-steroids. Systemic is segmented into methotrexate, retinoid, and cyclosporine.<\/p>\n

The global psoriasis treatment market, by drug class, is segmented into vitamin D analogues, tumour necrosis factor inhibitors, and Interleukin-inhibitors. Moreover, tumour necrosis factor inhibitors are further segmented into etanercept, adalimumab, and infliximab. Similarly, Interleukin-inhibitors is segmented into ustekinumab, secukinumab, ixekizumab, and brodalumab. Vitamin D analogues are segmented into calcitriol, calcipotriol, and tacalcitol.<\/p>\n

Psoriasis treatment market Regional Insights<\/p>\n

The global psoriasis treatment market covers the four regions, namely, the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).<\/p>\n

APAC can exhibit a stupendous growth rate during the forecast period owing to the expanding geriatric populace and the entry of market players in the region. Prescription of biologics and diagnostic tests used for development of customized therapies can drive the regional psoriasis treatment market growth. Clinical trials for the efficacy of alefacept and efalizumab conducted in Japan, South Korea, and Taiwan is an indicator of the huge potential of the market. On the other hand, the MEA region holds the lowest share of the global psoriasis treatment market owing to low economic development in Africa.<\/p>\n

The Americas can lead the psoriasis treatment market<\/a> owing to prevalence of psoriasis, awareness of treatment methods among the masses, and presence of prominent drug manufacturers. Prescribed treatments of topical agents and phototherapy for patients in Canada and the U.S. and approval of biologics will augur favorably for the market.<\/p>\n

Table of Content:<\/strong><\/p>\n

1 REPORT PROLOGUE<\/strong><\/p>\n

2 MARKET INTRODUCTION<\/strong>
Definition
Scope Of The Study
Research Objective
Assumptions
Limitations<\/p>\n

3 RESEARCH METHODOLOGY<\/strong>
Overview
Primary Research
Secondary Research
Market Size Estimation<\/p>\n

4 MARKET DYNAMICS<\/strong>
Overview
Drivers
Restraints
Opportunities<\/p>\n

5 MARKET FACTOR ANALYSIS<\/strong>
Porter’s Five Forces Analysis
Bargaining Power Of Suppliers
Bargaining Power Of Buyers
Threat Of New Entrants
Threat Of Substitutes
Intensity Of Rivalry
Value Chain Analysis<\/p>\n

TOC Continued………<\/p>\n

Browse Complete Research Report with COVID-19 Impact Analysis at:  <\/strong>https:\/\/www.marketresearchfuture.com\/reports\/psoriasis-treatment-market-2769<\/strong><\/a><\/p>\n

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Market Research Future<\/a>
Contact Person:<\/strong> Abhishek Sawant
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9312
Address:<\/strong>Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.marketresearchfuture.com\/reports\/psoriasis-treatment-market-2769<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Psoriasis Treatment Market Psoriasis Treatment Market Size, Growth and Share Analysis by Drug Class [Tumour Necrosis Factor Inhibitors, Interleukin-Inhibitors, Vitamin D Analogues, Treatment Type, Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics and Regional Insights (Americas, Europe, Asia-Pacific and Middle East & … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[417,412,406,404,416],"tags":[],"class_list":["post-495270","post","type-post","status-publish","format-standard","hentry","category-Marketing-Sales","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=495270"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=495270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=495270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=495270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}